Evidence map›Paper›PMID 26714983›Full record

ArticleLasers in medical science2016

Anti-inflammatory and lymphangiogenetic effects of low-level laser therapy on lymphedema in an experimental mouse tail model.

Dae-Hyun Jang, Da-Hyun Song, Eun-Ju Chang, Jae Yong Jeon

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Lasers in medical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07072780 (Effectiveness of a Novel Low-level Laser Therapy Protocol in Managing Breast Cancer-Related Lymphedema), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07072780 nacompletednot on this mapstarted 2023, after this paper: background citation

Effectiveness of a Novel Low-level Laser Therapy Protocol in Managing Breast Cancer-Related Lymphedema

TypeinterventionalSponsorPusan National University HospitalRan2023 to 2024Enrolled46ConditionsBreast CancerArmsLow-Level Laser Therapy (904 nm), Low-Level Laser Therapy (650 nm), Sham Laser Therapy
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Long-pulsed 1064-nm neodymium: yttrium-aluminum-garnet laser alleviates rosacea by improving lymphatic vessel dysfunction.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Evaluation of Efficacy of Low-Level Laser Therapy.Journal of lasers in medical sciences · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Dae-Hyun JangDepartment of Rehabilitation Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.
Da-Hyun SongDepartment of Biomedical Sciences, Asan Medical Center, College of Medicine, University of Ulsan, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
Eun-Ju ChangDepartment of Biomedical Sciences, Asan Medical Center, College of Medicine, University of Ulsan, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, Republic of Korea. ejchang@amc.seoul.kr.
Jae Yong JeonDepartment of Rehabilitation Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 138-736, Republic of Korea. jyjeon71@gmail.com.
University of Ulsan · KRAsan Medical Center · KRIncheon St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the therapeutic mechanism of low-level laser therapy (LLLT) in the mouse tail lymphedema model. Six-week-old female mice were classified into the laser treatment group, sham treatment group, and surgical control group (10 mice per group). LLLT was administered daily for 10 min from the surgical day to 11 days (12 times). Macrophage activation and lymphatic vessel regeneration were evaluated through immunohistochemical staining with anti-F4/80 and anti-LYVE-1 antibodies, respectively, at 12 days post-procedure. Quantitative real-time polymerase chain reaction (qPCR) was performed to measure messenger RNA (mRNA) expression of vascular endothelial growth factor A, B, C, R1, R2, and R3 (VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, and VEGFR3) at 12 days post-procedure. Student's t and one-way ANOVA tests were performed for statistical analyses. Significance was defined as p < 0.05. The thickness of the tail rapidly increased until 6 days in the laser and sham groups. The mice in the laser group showed a significantly decreased thickness compared with the sham group at 10 and 12 days. Immunohistochemistry assay revealed that LLLT reduced inflammation and induced new lymphatic vessel growth. qPCR showed that expressions of VEGFR3 were (p = 0.002) increased in the laser group. These results suggest that LLLT has anti-inflammatory and lymphangiogenetic effects for the management of lymphedema.

Indexed as

Low-Level Light TherapyAnimalsDisease Models, AnimalFemaleGene Expression RegulationInflammationLymphangiogenesisLymphatic VesselsLymphedemaMacrophage ActivationMiceReceptors, Vascular Endothelial Growth FactorRegenerationRNA, MessengerVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorRNA, MessengerVascular Endothelial Growth Factor ALow-level laser therapyLymphangiogenesisLymphedemaVascular endothelial growth factor C

Identifiers

PMID26714983
OpenAlexW2279676508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.